Agios Pharmaceuticals Inc (NASDAQ:AGIO) has been given an average rating of “Buy” by the fifteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $100.83.
Several equities analysts have recently weighed in on the company. Oppenheimer reissued a “market perform” rating on shares of Agios Pharmaceuticals in a report on Wednesday, February 20th. ValuEngine raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. BidaskClub cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Svb Leerink raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a report on Friday, February 15th. Finally, Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 12th.
In related news, insider Christopher Bowden sold 10,000 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $64.16, for a total value of $641,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction on Friday, April 5th. The stock was sold at an average price of $67.71, for a total value of $203,130.00. Following the completion of the transaction, the insider now directly owns 29,511 shares in the company, valued at $1,998,189.81. The disclosure for this sale can be found here. Insiders have sold a total of 42,000 shares of company stock worth $2,765,530 over the last three months. Insiders own 3.02% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. FMR LLC raised its holdings in Agios Pharmaceuticals by 0.3% in the 4th quarter. FMR LLC now owns 8,726,801 shares of the biopharmaceutical company’s stock worth $402,393,000 after purchasing an additional 27,915 shares during the period. BlackRock Inc. raised its holdings in Agios Pharmaceuticals by 1.2% in the 3rd quarter. BlackRock Inc. now owns 3,285,842 shares of the biopharmaceutical company’s stock worth $253,404,000 after purchasing an additional 37,591 shares during the period. Wealthstreet Investment Advisors LLC raised its holdings in Agios Pharmaceuticals by 15.9% in the 4th quarter. Wealthstreet Investment Advisors LLC now owns 29,165 shares of the biopharmaceutical company’s stock worth $1,473,000 after purchasing an additional 4,000 shares during the period. Millennium Management LLC raised its holdings in Agios Pharmaceuticals by 289.7% in the 4th quarter. Millennium Management LLC now owns 215,902 shares of the biopharmaceutical company’s stock worth $9,955,000 after purchasing an additional 160,493 shares during the period. Finally, Handelsbanken Fonder AB raised its holdings in Agios Pharmaceuticals by 12.4% in the 4th quarter. Handelsbanken Fonder AB now owns 195,000 shares of the biopharmaceutical company’s stock worth $8,991,000 after purchasing an additional 21,500 shares during the period. 98.77% of the stock is currently owned by institutional investors.
AGIO traded down $1.50 during trading on Wednesday, hitting $59.82. 5,433 shares of the company’s stock traded hands, compared to its average volume of 404,074. Agios Pharmaceuticals has a 12-month low of $41.63 and a 12-month high of $99.82. The company has a market cap of $3.53 billion, a price-to-earnings ratio of -9.96 and a beta of 2.38.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the consensus estimate of ($1.65) by $0.07. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The business had revenue of $30.00 million for the quarter, compared to the consensus estimate of $19.98 million. During the same period last year, the business posted ($1.81) EPS. The company’s revenue was up 200.0% compared to the same quarter last year. Equities analysts expect that Agios Pharmaceuticals will post -6.73 earnings per share for the current fiscal year.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Read More: Dividend
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.